A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a phase III multi-centre study in two periods: the first period is a phosphate binder
and lipid lowering drugs washout for 8 weeks, the second period is a double-blind,
randomised, parallel group, fixed dose, for 12 weeks.